The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The HELIOS network: disseminating knowledge on hemoglobinopathies
In this interview, Petros Kountouris, PhD, The Cyprus Institute of Neurology & Genetics, Lefkosia, Cyprus, introduces the HELIOS (Hemoglobinopathies in European Liaison of Medicine and Science) network and outlines its primary goals. This initiative aims to disseminate the existing knowledge on hemoglobinopathies, including sickle cell disease (SCD) and thalassemia, through specialized training programs in the hope that this will advance healthcare systems, inform policymaking, and improve patient outcomes. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, HELIOS is a global network that is funded by the COST Association and aims to bring together experts and different stakeholders in the field of hemoglobinopathies. The main aim is to develop a comprehensive training program for hemoglobinopathies on different topics that include molecular research and diagnosis, clinical management, data management, dissemination and outreach. So all topics that are related to the field of hemoglobinopathies are covered...
So, HELIOS is a global network that is funded by the COST Association and aims to bring together experts and different stakeholders in the field of hemoglobinopathies. The main aim is to develop a comprehensive training program for hemoglobinopathies on different topics that include molecular research and diagnosis, clinical management, data management, dissemination and outreach. So all topics that are related to the field of hemoglobinopathies are covered. It’s an open network. Anyone can join from anywhere in the world. So it started last year and we have already included in the network around 200 people, so it’s maybe one of the largest networks in the field, and we have developed already several training activities like webinars, face-to-face training schools, discussion clubs with early career researchers and we are hopeful that in the next three years, that is the duration of the project, we will develop even more for the project.
Read more...
Disclosures
Research funding: Agios Pharmaceuticals.
